clinical trial · NCT07671911
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Idiopathic Pulmonary FibrosisNAL ERPlacebo
brief summary
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
started
Jun 29, 2026
primary completion
Jun 1, 2028
completion
Jul 1, 2028
last updated
Jul 10, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol